Zhang Qunchen, Fang Yutong, She Chuanghong, Zheng Rongji, Hong Chaoqun, Chen Chunfa, Wu Jundong
The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.
Department of Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.
Exp Ther Med. 2022 Aug 5;24(4):616. doi: 10.3892/etm.2022.11553. eCollection 2022 Oct.
There is a lack of validated biomarkers for the diagnosis of early breast cancer (EBC). The current study aimed to determine the diagnostic and prognostic value of solute carrier family 50 member 1 (SLC50A1) in patients with EBC. Therefore, 123 patients with EBC, 30 patients with benign breast disease (BBD) and 26 healthy controls (HCs) were recruited. The serum levels of SLC50A1 in paired sera of 40 postoperative patients were assessed by ELISA. Immunohistochemical staining for SLC50A1 was performed in surgical tissue derived from 83 patients with EBC and 30 patients with BBD. mRNA expression of SLC50A1 and its diagnostic and prognostic value in patients with EBC was evaluated using an RNA-sequencing database. The results showed that serum levels of SLC50A1 in patients with EBC were significantly higher compared with those in patients with BBD and HCs (both P<0.001). Additionally, receiver operating characteristic curve analysis revealed that the serum levels of SLC50A1 distinguished patients with EBC from patients with BBD and HCs with a sensitivity of 76.42% and specificity of 76.79% [area under the curve (AUC)=0.783; P<0.001]. The diagnostic value of SLC50A1 was significantly greater than that of carcinoembryonic (P<0.005) and carbohydrate antigen 15-3 (P<0.029). Furthermore, the number of SLC50A1 positive cells significantly increased in tissue of patients with EBC compared with patients with BBD (P<0.001). A positive association between serum levels of SLC50A1 and its expression in tissue samples was observed in patients with EBC (ρ=0.700; P<0.001). Additionally, bioinformatics analysis verified the diagnostic value of SLC50A1, with an AUC of 0.983 (P<0.001). Multivariate analysis demonstrated that SLC50A1 was an independent prognostic factor in patients with EBC with a hazard ratio of 1.917 (P=0.013). These findings indicated that SLC50A1 may be a potential diagnostic biomarker for primary EBC and that SLC50A1 upregulation may be associated with unfavorable prognosis in patients with EBC.
早期乳腺癌（EBC）的诊断缺乏经过验证的生物标志物。本研究旨在确定溶质载体家族50成员1（SLC50A1）在EBC患者中的诊断和预后价值。因此，招募了123例EBC患者、30例乳腺良性疾病（BBD）患者和26例健康对照（HC）。采用酶联免疫吸附测定（ELISA）评估40例术后患者配对血清中SLC50A1的血清水平。对83例EBC患者和30例BBD患者手术组织进行SLC50A1免疫组织化学染色。利用RNA测序数据库评估EBC患者中SLC50A1的mRNA表达及其诊断和预后价值。结果显示，EBC患者血清SLC50A1水平显著高于BBD患者和HC（均P<0.001）。此外，受试者工作特征曲线分析显示，SLC50A1血清水平区分EBC患者与BBD患者和HC，灵敏度为76.42%，特异性为76.79%[曲线下面积（AUC）=0.783；P<0.001]。SLC50A1的诊断价值显著大于癌胚抗原（P<0.005）和糖类抗原15-3（P<0.029）。此外，与BBD患者相比，EBC患者组织中SLC50A1阳性细胞数量显著增加（P<0.001）。在EBC患者中观察到血清SLC50A1水平与其在组织样本中的表达呈正相关（ρ=0.700；P<0.001）。此外，生物信息学分析验证了SLC50A1的诊断价值，AUC为0.983（P<0.001）。多因素分析表明，SLC50A1是EBC患者的独立预后因素，风险比为1.917（P=0.013）。这些发现表明，SLC50A1可能是原发性EBC的潜在诊断生物标志物，且SLC50A1上调可能与EBC患者预后不良相关。
